We recently received an update from TapImmune Inc. (TPIV-OTC.BB) regarding the Company's newly acquired laboratory and office space in South Lake Union (Seattle's up-and-coming biotech hub). Through a strategic sublease with the Puget Sound Blood Center Research Institute, TapImmune's scientific research team now has access to shared equipment and state-of-the-art core laboratories for DNA sequencing, Mass Spectrometry (shown below), and Fluorescent Activated Cell Sorting (FACS)—a unique opportunity for any startup company.
This corporate milestone not only provides TapImmune the opportunity to immediately begin delivery of the Company’s gene-based product candidates for clinical trials but also supports the Company’s external R&D collaborations.
We are very excited to be working with the Puget Sound Blood Center's internationally-recognized group of scientific investigators since this allows a leveraging of our development dollars in a way that expands our capabilities well beyond our core staff.
~ Dr. Mark Reddish, TapImmune's VP of Product Development, Jan. 18, 2012
Dr. Reddish was brought on board in November 2011 due to his experience developing immunotherapy products for both cancer and biodefense. At Biomira Inc. (now Oncothyreon Inc. [ONTY-NASDAQ]), he was responsible for preclinical development of the cancer vaccines program, where he led the early R&D of the Stimuvax® cancer vaccine, which is now in Phase III clinical trials under a partnership with Merck KGaA (MRK-XETRA). As well, he was the former vice president of product development and principal investigator, biodefense at ID Biomedical Corp. before its acquisition by GlaxoSmithKline plc (GSK-NYSE) for $1.4 billion in late 2005.
Going forward, Dr. Reddish will have a key role in TapImmune’s development operations and the progression of its product pipeline, particularly as the Company opens its new Seattle-based labs. TapImmune planned to move into the facility imminently.